Search

Your search keyword '"Turner, N"' showing total 1,801 results
Start Over Author "Turner, N" Publication Type Academic Journals
1,801 results on '"Turner, N"'

1. A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

Author

Hamilton, E., Oliveira, M., Turner, N., García-Corbacho, J., Hernando, C., Ciruelos, E.M., Kabos, P., Ruiz-Borrego, M., Armstrong, A., Patel, M.R., Vaklavas, C., Twelves, C., Boni, V., Incorvati, J., Brier, T., Gibbons, L., Klinowska, T., Lindemann, J.P.O., Morrow, C.J., Sykes, A., and Baird, R.D.

Published
2024
Full Text
View/download PDF

2. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

Author

Aebi, S., Al-Foheidi, M., André, F., Anikusko, M., Badwe, R., Barrio, A.V., Barrios, C., Bergh, J., Bonnefoi, H., Bretel Morales, D., Brucker, S., Burstein, H.J., Caldas, C., Cameron, D., Cardoso, F., Cardoso, M.J., Carey, L., Chia, S., Coles, C., Cortes, J., Curigliano, G., de Boniface, J., Delaloge, S., DeMichele, A., Denkert, C., Fastner, G., Fitzal, F., Francis, P., Gamal, H., Gentilini, O., Gnant, M., Gradishar, W., Gulluoglu, B., Harbeck, N., Heil, J., Huang, C.-S.H., Huober, J., Jiang, Z., Kaidar-Person, O., Kok, M., Lee, E.-S., Loi, S., Loibl, S., Martin, M., Meattini, I., Morrow, M., Partridge, A., Penault-Llorca, F., Piccart, M., Pierce, L., Poortmans, P., Regan, M., Reis-Filho, J., Rubio, I., Rugo, H., Rutgers, E., Saura, C., Senkus, E., Shao, Z., Singer, C., Spanic, T., Thuerlimann, B., Toi, M., Tolaney, S., Turner, N., Tutt, A., Vrancken Peeters, M.-J., Watanabe, T., Weber, W., Wildiers, H., Xu, B., Regan, M.M., Weber, W.P., and Thürlimann, B.

Published
2023
Full Text
View/download PDF

3. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Author

Bachelot, T., Bouzid, K., Campone, M., Desmoulins, I., Coudert, B., Bondarenko, I., Nowecki, Z., Glogowska, I., Ciruelos Gil, E., Errihani, H., Dalenc, F., Ricci, F., Dieras, V., Kaufman, B., Paluch-Shimon, S., Wardley, A., Schneeweiss, A., Ferreira, A., Mano, M., Kalofonos, H., Andreetta, C., Puglisi, F., Montemurro, F., Barrett, S., Zhang, Q., Mavroudis, D., Matus, J., Villarreal Garza, C., Beato, C., Ismael, G., Hu, X., Abdel Azeem, H., Gaafar, R., Perrin, C., Kerbrat, P., Ettl, J., Paepke, S., Hitre, E., Lang, I., Trudeau, M., Verma, S., Li, H., Hoffmann, O., Aktas, B., Cariello, A., Cruciani, G., Tienghi, A., Tondini, C., Al-Twegieri, T., Loman, N., Laing, R., Miles, D., Brain, E., Fasching, P., Lux, M., Frassoldati, A., Aziz, Z., Salas, J., Streb, J., Krzemieniecki, K., Wronski, A., Garcia Garcia, J., Menjon Beltran, S., Cicin, I., Schmid, P., Gallagher, C., Turner, N., Tong, Z., Boer, K., Juhász, B., Horvath, Z., Bianchini, G., Gianni, L., Curigliano, G., Juarez Ramiro, A., Susnjar, S., Matos, E., Sevillano, E., Garcia Estevez, L., Gokmen, E., Uslu, R., Wildiers, H., Schutz, F., Cruz, M., Bourgeois, H., von Schumann, R., Stemmer, S., Dominguez, A., Morales-Vásques, F., Wojtukiewicz, M., Trifunovic, J., Echarri Gonzalez, M.J., Illarramendi Mañas, J., Martinez De Dueñas, E., Voitko, N., Hicks, J., Waters, S., Barrett-Lee, P., Wheatley, D., De Boer, R., Cocquyt, V., Jerusalem, G., Barrios, C., Panasci, L., Mattson, J., Tanner, M., Gozy, M., Vasilopoulos, G., Papandreou, C., Revesz, J., Battelli, N., Benedetti, G., Latini, L., Gridelli, C., Lazaro Leon, J., Alarcón Company, J., Arance Fernandez, A., Barnadas Molins, A., Calvo Plaza, I., Bratos, R., Gonzalez Martin, A., Izarzugaza Peron, Y., Klint, L., Kovalev, A., McCarthy, N., Yeo, B., Kee, D., Thomson, J., White, S., Greil, R., Wang, S., Artignan, X., Juhasz-Böess, I., Rody, A., Ngan, R., Dourleshter, F., Goldberg, H., Doni, L., Di Costanzo, F., Ferraù, F., Drobniene, M., Aleknavicius, E., Rashid, K., Costa, L., de la Cruz Merino, L., Garcia Saenz, J., López, R., Del Val Munoz, O., Ozyilkan, O., Azribi, F., Jaafar, H., Baird, R., Verrill, M., Beith, J., Petzer, A., Moreira de Andrade, J., Bernstein, V., Macpherson, N., Rayson, D., Saad Eldin, I., Achille, M., Augereau, P., Müller, V., Rasco, A., Evron, E., Katz, D., Berardi, R., Cascinu, S., De Censi, A., Gennari, A., El-Saghir, N., Ghosn, M., Oosterkamp, H.M., Van den Bosch, J., Kukulska, M., Kalinka, E., Alonso, J., Dalmau Portulas, E., Del Mar Gordon Santiago, M., Pelaez Fernandez, I., Aksoy, S., Altundag, K., Senol Coskun, H., Bozcuk, H., Shparyk, Y., Barraclough, L., Levitt, N., Panwar, U., Kelly, S., Rigg, A., Varughese, M., Castillo, C., Fein, L., Malik, L., Stuart-Harris, R., Singer, C., Stoeger, H., Samonigg, H., Feng, J., Cedeño, M., Ruohola, J., Berdah, J.-F., Goncalves, A., Orfeuvre, H., Grischke, E.-M., Simon, E., Wagner, S., Koumakis, G., Papazisis, K., Ben Baruch, N., Fried, G., Geffen, D., Karminsky, N., Peretz, T., Cavanna, L., Pedrazzioli, P., Grasso, D., Ruggeri, E., D’Auria, G., Moscetti, L., Juozaityte, E., Rodriguez Cid, J., Roerdink, H., Siddiqi, N., Passos Coelho, J., Arcediano Del Amo, A., Garcia Garre, E., García Gonzalez, M., Garcia-Palomo Perez, A., Herenandez Perez, C., Lopez Alvarez, P., Lopez De Ceballos, M.H., Martínez Jañez, N., Mele Olive, M., McAdam, K., Perren, T., Dunn, G., Humphreys, A., Taylor, W., Vera, R., Kaen, L., Andel, J., Steger, G., De Grève, J., Huizing, M., Hegg, R., Joy, A., Kuruvilla, P., Sehdev, S., Smiljanic, S., Kütner, R., Alexandre, J., Grosjean, J., Laplaige, P., Largillier, R., Maes, P., Martin, P., Pottier, V., Christensen, B., Khandan, F., Lück, H.-J., Zahm, D.-M., Fountzilas, G., Karavasilis, V., Safra, T., Inbar, M., Ryvo, L., Bonetti, A., Seles, E., Giacobino, A., Chavarri Guerra, Y., de Jongh, F., van der Velden, A., van Warmerdam, L., Vrijaldenhoven, S., Smorenburg, C.H., Cavero, M., Andres Conejero, R., Oltra Ferrando, A., Redondo Sanchez, A., Ribelles Entrena, N., Saura Grau, S., Viñas Vilaro, G., Bachmeier, K., Beresford, M., Butt, M., Joffe, J., Poole, C., Woodings, P., Chakraborti, P., Yordi, G., Woodward, N., Nobre, A., Luiz Amorim, G., Califaretti, N., Fox, S., Robidoux, A., Li, E., Li, N., Jiang, J., Soria, T., Padrik, P., Lahdenpera, O., Barletta, H., Dohollou, N., Genet, D., Prulhiere, K., Coeffic, D., Facchini, T., Vieillot, S., Catala, S., Teixeira, L., Hesse, T., Kühn, T., Ober, A., Repp, R., Schröder, W., Pectasides, D., Bodoky, G., Kahan, Z., Jiveliouk, I., Rosengarten, O., Rossi, V., Alabiso, O., Pérez Martínez, M., van de Wouw, A.J., Smok-Kalwat, J., Damasecno, M., Augusto, I., Sousa, G., Saadein, A., Abdelhafiez, N., Abulkhair, O., Antón Torres, A., Corbellas Aparicio, M., Llorente Domenech, R., Florián Jerico, J., Garcia Mata, J., Gil Raga, M., Galan Brotons, A., Llombart Cussac, A., Llorca Ferrandiz, C., Martinez Del Prado, P., Olier Garate, C., Rodriguez Sanchez, C., Sanchez Gomez, R., Santisteban Eslava, M., Soberino, J., Vidal Losada Garcia, M., Soto de Prado, D., Torrego Garcia, J., Vicente Rubio, E., Garcia, M., Murias Rosales, A., Granstam Björneklett, H., Narbe, U., Jafri, M., Rea, D., Newby, J., Jones, A., Westwell, S., Ring, A., Alonso, I., Rodríguez, R., Ciruelos, E., Peretz-Yablonski, T., Merot, J.-L., Trask, P., du Toit, Y., Pena-Murillo, C., Revelant, V., and Klingbiel, D.

Published
2021
Full Text
View/download PDF

5. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

Author

Martin, M., Zielinski, C., Ruiz-Borrego, M., Carrasco, E., Turner, N., Ciruelos, E.M., Muñoz, M., Bermejo, B., Margeli, M., Anton, A., Kahan, Z., Csöszi, T., Casas, M.I., Murillo, L., Morales, S., Alba, E., Gal-Yam, E., Guerrero-Zotano, A., Calvo, L., de la Haba-Rodriguez, J., Ramos, M., Alvarez, I., Garcia-Palomo, A., Huang Bartlett, C., Koehler, M., Caballero, R., Corsaro, M., Huang, X., Garcia-Sáenz, J.A., Chacón, J.I., Swift, C., Thallinger, C., and Gil-Gil, M.

Published
2021
Full Text
View/download PDF

6. Radiology Readiness for Monkeypox: Experience from an Epicenter of the Public Health Emergency.

Author

Liszewski, Mark C., Chiang, Andrew, Gendlina, Inessa, Jain, Ruchika, Turner, Nancy, Yee, Judy, Liszewski, M C, Chiang, A, Gendlina, I, Jain, R, Turner, N, and Yee, J

Abstract

Monkeypox is a viral illness that became a global outbreak in 2022. Given the emerging public health threat, it is essential that Radiology Departments are prepared. This article reviews key information for Radiologists and Radiology Department Staff, including clinical features, the potential role for imaging, possible imaging findings, and suggested procedures for safely obtaining imaging studies in patients diagnosed with or suspected of having monkeypox. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Recruiting Young People to Sensitive Research: Turning the 'Wheels within Wheels'

Author

Turner, N. and Almack, K.

Abstract

This article contributes to a growing literature that takes a more nuanced approach to exploring the complexities of relationships and negotiations with gatekeepers. Using our study of young people living with a parent at the end of life as a 'critical case' of sensitive qualitative research, we discuss how far from being a smooth, linear process, participant recruitment was experienced as a series of overlapping challenges, characterised here as 'wheels within wheels'. Each component of this multi-faceted process relied on identifying and engaging with key practitioners who acted as gatekeepers. We discuss how researcher and gatekeeper positionality influenced the outcome of negotiations with gatekeepers, and highlight potential implications for young people in exigent sets of circumstances. If the routes 'in' to access young people are difficult, then this also raises questions about routes 'out' for young people and their access to support when living through challenging times.

Published
2017
Full Text
View/download PDF

21. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.

Author

Turner, N. C., Oliveira, M., Howell, S. J., Dalene, F., Cortes, J., Moreno, H. L. Gomez, Hu, X., Jhaveri, K., Krivorotko, P., Loibl, S., Murillo, S. Morales, Okera, M., Park, Y. H., Sohn, J., Toi, M., Tokunaga, E., Yousef, S., Zhukova, L., de Bruin, E. C., and Grinsted, L.

Abstract

BACKGROUND AKT pathway activation is implicated in endocrine-therapy resistance. Data on the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy, in patients with hormone receptor-positive advanced breast cancer are limited. METHODS In a phase 3, randomized, double-blind trial, we enrolled eligible pre-, peri-, and postmenopausal women and men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer who had had a relapse or disease progression during or after treatment with an aromatase inhibitor, with or without previous cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor therapy. Patients were randomly assigned in a 1:1 ratio to receive capivasertib plus tor-assessed progression-free survival assessed both in the overall population and among patients with AKT pathway-altered (PIK3CA, AKT1, or PTEN) tumors. Safety was assessed. RESULTS Overall, 708 patients underwent randomization; 289 patients 040.8°6) had AKT pathway alterations, and 489 (69.1%) had received a CDK4/6 inhibitor previously for advanced breast cancer. In the overall population, the median progression-free survival was 7.2 months in the capivasertib-fulvestrant group, as compared with 3.6 months in the placebo-fulvestrant group (hazard ratio for progression or death, 0.60; 95% confidence interval ICI], 0.51 to 0.71; P<0.001). In the AKT pathway-altered population, the median progression-free survival was 7.3 months in the capivasertib-fulvestrant group, as compared with 3.1 months in the placebofulvestrant group (hazard ratio, 0.50; 95% CI, 0.38 to 0.65; P<0.001). The most frequent adverse events of grade 3 or higher in patients receiving capivasertibfulvestrant were rash (in 12.1% of patients, vs. in 0.3% of those receiving placebofulvestrant) and diarrhea (in 9.396 vs. 0.396). Adverse events leading to discontinuation were reported in 13.0% of the patients receiving capivasertib and in 2.3°6 of those receiving placebo. CONCLUSIONS Capivasertib-fulvestrant therapy resulted in significantly longer progression-free survival than treatment with fulvestrant alone among patients with hormone receptor-positive advanced breast cancer whose disease had progressed during or after previous aromatase inhibitor therapy with or without a CDK4/6 inhibitor. (Funded by AstraZeneca and the National Cancer Institute. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. Previous vaccination modifies both the clinical disease and immunological features in children with measles

Author

Mitchell P, Turner N, Jennings L, and Dong H

Subjects
Immunoglobulin M, measles, measles-mumps-rubella vaccine, polymerase chain reaction, vaccination, Public aspects of medicine, RA1-1270
Abstract

INTRODUCTION: Measles that develops in previously vaccinated cases has been reported to be associated with modified disease, although severity has usually been assessed by the presence or absence of symptoms. To date no studies have attempted to subjectively grade the severity of the clinical features. AIM: To investigate both the objective and subjective severity of measles in vaccinated and unvaccinated cases in the context of a community outbreak. METHODS: A retrospective observational cohort study conducted in Christchurch in 2009 using notified data compared the presentation of measles in 14 confirmed cases that had received at least one MMR (measles, mumps, rubella) vaccination and 14 age-matched unvaccinated confirmed cases. Additional details on the subjective and objective severity of the illness were obtained from parents/guardians using a standardised telephone questionnaire. RESULTS: The vaccinated group had significantly fewer clinical features on presentation (p=0.01, RR=1.3, 95% CI 1.1-1.6) and a less severe illness objectively, as measured by height and duration of fever, the number of days needing medication other than paracetamol and days required in bed. Unvaccinated cases were 2.8 times more likely to have more severe clinical features than vaccinated cases (OR=2.8, 95% CI 1.5-5.0). Unvaccinated cases were 3.0 times more likely to develop IgM antibody (RR=3.0, 95% CI 0.9-9.3). DISCUSSION: Previously vaccinated children who develop measles are likely to have less severe disease and serology results that may be inconclusive, particularly for IgM antibody if tested in the first few days after the rash onset.

Published
2013

28. MMS Observations of Dayside Warm (Several eV to 100 eV) Ions in the Middle and Outer Magnetosphere.

Author

Goldstein, J., Burch, J. L., Fuselier, S. A., Gomez, R., Gonzalez, C. A., Kim, M. J., Mukherjee, J., Turner, N. E., and Wilson, M. E.

Subjects
MAGNETOSPHERE, EARTH (Planet), ION traps, TOROIDAL plasma, ION analysis, ION temperature
Abstract

Warm (several eV to 100 eV) ions are an important, and still poorly understood, component of the magnetospheric plasma environment. We present the first comprehensive statistical analysis of several distinct populations of warm ions in the dayside middle and outer magnetosphere. We analyze 7 months (1 September 2015–31 March 2016) of Magnetospheric Multiscale Hot Plasma Composition Analyzer data comprising 734,200 moments (density, temperature) and energy‐dependent pitch angle distributions (PADs) of three major ion species (H+, He+, and O+) with energy ≤100 eV. PADs are represented by an energy‐averaged index that characterizes the shape of the PAD as field‐aligned (FA), pancake, or isotropic. We use filtering by temperature, pitch angle, and concentration to distinguish different populations, and obtain new and more complete information about average density, temperature, PADs, and composition. Our analysis explores two known populations of warm ions: the warm plasmasphere (WPS) and the warm cloak/trough (C/T). The WPS is a higher‐temperature, higher‐L extension of the duskside plasmaspheric bulge, containing mostly trapped (pancake/isotropic) ions with an H+:He+:O+ order of ion dominance. The C/T contains mostly FA warm ions with a dawnward (duskward) temperature gradient for H+ (He+ and O+), lower densities, and an H+:O+:He+ order of ion dominance. The WPS‐C/T overlap contains a mixture of the two populations (e.g., FA He+ in WPS, trapped O+ in C/T). Pancake (FA) PADs are correlated with higher (lower) density/temperature. Our analysis also identifies warm ions in the low‐energy plasma sheet. Our work consolidates and systematically extends the characterizations of warm ions reported in previous studies. Plain Language Summary: The plasmasphere is often defined as the cold and dense innermost region of the magnetosphere. The ring current may be defined as the torus of hot ions encircling the planet at several Earth radii of geocentric distance. Warm plasma (several eV to 100 eV) is an intermediate‐energy population. In this paper, we present the first comprehensive statistical analysis of several distinct populations of warm ions in the dayside middle and outer magnetosphere. We analyze 7 months (1 September 2015–31 March 2016) of data from the Magnetospheric Multiscale mission. Several‐eV to 100‐eV ions constitute a large reservoir of mass and momentum that can influence numerous basic, system‐level aspects of the magnetosphere. Warm ions are also a "bridge population" whose intermediate‐energy dynamics reveal heating and energization processes that trap ions to enable plasmaspheric refilling and transform very cold, ionospheric‐origin plasma into an integral component of the stormtime plasma sheet and ring current. Key Points: Statistical analysis of dayside warm (≤100 eV) ions uses 734,200‐point database of density, temperature, and pitch angle (PA) distributionsFiltering by temperature, PA, and concentration helps distinguish and separate different warm ion populationsThis analysis consolidates and systematically extends the characterizations of the warm plasmasphere and the warm cloak/trough (C/T) [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. HD 181068: A Red Giant in a Triply Eclipsing Compact Hierarchical Triple System

Author

Derekas, A., Kiss, L. L., Borkovits, T., Huber, D., Lehmann, H., Southworth, J., Bedding, T. R., Balam, D., Hartmann, M., Hrudkova, M., Ireland, M. J., Kovács, J., Mező, Gy., Moór, A., Niemczura, E., Sarty, G. E., Szabó, Gy. M., Szabó, R., Telting, J. H., Tkachenko, A., Uytterhoeven, K., Benkő, J. M., Bryson, S. T., Maestro, V., Simon, A. E., Stello, D., Schaefer, G., Aerts, C., Brummelaar, T. A. ten, De Cat, P., McAlister, H. A., Maceroni, C., Mérand, A., Still, M., Sturmann, J., Sturmann, L., Turner, N., Tuthill, P. G., Christensen-Dalsgaard, J., Gilliland, R. L., Kjeldsen, H., Quintana, E. V., Tenenbaum, P., and Twicken, J. D.

Published
2011
Full Text
View/download PDF

35. Imaging the Surface of Altair

Author

Monnier, John D., Zhao, M., Pedretti, E., Thureau, N., Ireland, M., Muirhead, P., Berger, J.-P., Millan-Gabet, R., Van Belle, G., Brummelaar, T. ten, McAlister, H., Ridgway, S., Turner, N., Sturmann, L., Sturmann, J., and Berger, D.

Published
2007
Full Text
View/download PDF

43. 386MO Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial

Author

Aftimos, P.G., Turner, N., O'Shaughnessy, J., van den Tweel, E., Oesterholt, M., Escrivá-de-Romaní, S., Tueux, N. Quenel, Tan, T.J.Y., Lim, J., Ladoire, S., Armstronh, A.C., Stradella, A., Bianchi, G.V., Colleoni, M.A., Kaczmarek, E., Punie, K., Song, X., Koper, N., and Manich, C. Saura

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results